LabVantage Named Global LIMS Company of the Year by Frost & Sullivan
12.9.2024 14:30:00 EEST | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, today announced it has been awarded the prestigious Company of the Year Award in the Global Laboratory Information Management Systems (LIMS) Industry by Frost & Sullivan. This recognition highlights LabVantage’s leadership in visionary innovation, performance, and customer impact, affirming the company’s commitment to delivering cutting-edge, customer-centric solutions across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912829381/en/
(Graphic: Business Wire)
The award, part of Frost & Sullivan’s Best Practices Awards series, acknowledges companies that demonstrate excellence in growth and innovation. LabVantage has been recognized for excelling in both dimensions, leveraging its visionary approach to address unmet needs in laboratory informatics while maintaining a strong focus on customer satisfaction and service experience. Over nearly four decades, the company has evolved from a specialized LIMS provider into a vertical Software-as-a-Service (SaaS) platform provider for all laboratory-related digital needs of various industries, including pharmaceuticals, biotechnology, food and beverage, oil and gas, contract testing, public health labs, forensics, and government.
“LabVantage distinguishes itself with an extensive product lineup, smooth integration capabilities, and dedication to facilitating digital transformation in laboratories,” said Lucila Martin, Healthcare & Life Sciences Research Analyst at Frost & Sullivan. “Given the early and strategic growth of SaaS as part of its business, the company enhances its ability to capitalize on LIMS market trends and opportunities.”
Additionally, LabVantage has been named a leader, for the second consecutive year, in the 2024 Frost Radar™ for Global LIMS for the life sciences industry – providing yet another testament to its continued leadership and adaptability in a rapidly evolving sector. In the Radar, Frost & Sullivan evaluated 50 LIMS vendors, plotting the top 14 for their advanced capabilities in interoperability, scalability, and configurability. Companies on the Radar adopt a robust vision focused on growth and rigorous innovation that promotes seamless integration of new technologies, identifies the critical needs of each area, and offers distinctive features for each use of their solutions. A leading player in this Radar analysis, LabVantage scored a high 4.6 on the Innovation index, and similarly, a 4.5 on the Growth index.
“It is a great honor to be awarded Company of the Year in the Global LIMS industry by an esteemed industry advisory firm such as Frost & Sullivan,” said Mikael Hagstroem, CEO of LabVantage Solutions. “This recognition is a result of the dedication and passion that my 1223 colleagues put into changing from a product-centric to a truly client-focused company with a focus on delivering client impact. Earning the Frost Radar recognition two years in a row is a humbling and rare feat for any company – for us, it underscores how closely we partner with our customers to drive innovation. We are proud that our efforts to listen to and innovate based on customer feedback are being recognized, validating our commitment to delivering impact and partnering with our clients for the betterment of the human condition.”
Customers benefit from LabVantage’s robust SaaS offerings, which enable continuous innovation, operational efficiency, and reduced capital expenditures. The company’s internal professional services team, which manages significant implementation work in-house, also plays a critical role in delivering impact that is consistently growing over time. For example, they help clients by shortening time for validation and providing services, such as instrument integration, master data management, and generative artificial intelligence (AI)-based augmentation. In April 2024, LabVantage achieved over 100 software deployments for fiscal year 2024 across the various industries it serves.
LabVantage continues to expand its global footprint, with strategic growth initiatives in Colombia, Brazil, South Korea, and Hong Kong, and has enhanced its capabilities through acquisitions, such as SEIN Infotech. The company’s investment in emerging technologies, including generative AI, is further solidifying its leadership in laboratory informatics, offering customers more intelligent and efficient systems.
For more information on LabVantage and its comprehensive LIMS solutions, visit www.labvantage.com or email info@labvantage.com.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise or via SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912829381/en/
Contacts
Media:
Charya Wickremasinghe, Ph.D.
Brandwidth Solutions
cwickremasinghe@brandwidthsolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom